Boehringer Hooks Up With Arena In CNS
This article was originally published in Scrip
Boehringer Ingelheim GmbH has agreed to pay up to $262m in milestones to Arena Pharmaceuticals, Inc. under a new R&D agreement. The two will jointly research and develop CNS drugs against an undisclosed G protein-coupled receptor (GPCR) whose ligand has not been identified. Arena will share internally discovered compounds and IP for the CNS receptor, and use technology it has developed to discover drugs targeting GPCRs even when their natural ligand is not known. Such receptors are known as "orphan GPCRs", and being able to analyze these as well as GPCRs with known ligands increases the chances of finding new therapies. BI hopes the alliance with Arena will lead to new treatments for psychiatric diseases such as schizophrenia. The German firm's only marketed CNS drug is Mirapex (pramipexole) for Parkinson's Disease, but it recently extended its R&D efforts in CNS beyond degenerative nerve diseases into psychiatric diseases.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.